Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.

Published Date: 15 Apr 2024

One-third of patients experience responses when using adagrasib plus cetuximab, with a median overall survival of 15 points 9 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Survival improved with lobectomy, segmentectomy in early non-small cell lung cancer

2.

Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.

3.

First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.

4.

A large study found that monolayers were superior in detecting cancer.

5.

Potentially Novel Approach for Treating Advanced Colorectal Cancer with KRAS Mutations.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot